Qiagen N.V. – NYSE:QGEN

Qiagen N.V. stock price today

$48.1
+3.10
+6.91%
Financial Health
0
1
2
3
4
5
6
7
8
9

Qiagen N.V. stock price monthly change

+6.66%
month

Qiagen N.V. stock price quarterly change

+6.66%
quarter

Qiagen N.V. stock price yearly change

+3.47%
year

Qiagen N.V. key metrics

Market Cap
9.94B
Enterprise value
10.92B
P/E
107.62
EV/Sales
5.55
EV/EBITDA
30.84
Price/Sales
5.07
Price/Book
2.83
PEG ratio
50.58
EPS
1.52
Revenue
1.93B
EBITDA
687.62M
Income
336.94M
Revenue Q/Q
-5.48%
Revenue Y/Y
-2.99%
Profit margin
4.73%
Oper. margin
5.92%
Gross margin
49.66%
EBIT margin
5.92%
EBITDA margin
35.47%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Qiagen N.V. stock price history

Qiagen N.V. stock forecast

Qiagen N.V. financial statements

Average Price Target
Last Year

$49

Potential upside: 1.87%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Qiagen N.V. (NYSE:QGEN): Profit margin
Jun 2023 494.85M 80.78M 16.33%
Sep 2023 475.89M 77.81M 16.35%
Dec 2023 509.16M 97.66M 19.18%
Mar 2024 458.79M 80.67M 17.58%
Qiagen N.V. (NYSE:QGEN): Debt to assets
Jun 2023 6347268000 2.72B 42.91%
Sep 2023 5906698000 2.21B 37.47%
Dec 2023 6115190000 2.30B 37.73%
Mar 2024 5805929000 2.20B 38%
Qiagen N.V. (NYSE:QGEN): Cash Flow
Jun 2023 111.47M 156.27M -15.47M
Sep 2023 124.68M 248.36M -401.09M
Dec 2023 151.36M -58.45M -7.43M
Mar 2024 133.07M 6.43M -292.08M

Qiagen N.V. alternative data

Qiagen N.V. (NYSE:QGEN): Employee count
Sep 2023 6,100
Oct 2023 6,100
Nov 2023 6,100
Dec 2023 6,000
Jan 2024 6,000
Feb 2024 6,000
Mar 2024 5,191
Apr 2024 5,191
May 2024 5,191
Jun 2024 5,900
Jul 2024 5,900

Qiagen N.V. other data

59.88% +2.55%
of QGEN is owned by hedge funds
138.94M +4.66M
shares is hold by hedge funds
Insider Compensation
Mr. Thierry Bernard (1965) Chief Executive Officer, MD & Member of Management Board $2,410,000
Dr. Roland Sackers (1968) Chief Financial Officer, MD & Member of Management Board
$977,500
Friday, 13 December 2024
zacks.com
zacks.com
Thursday, 12 December 2024
businesswire.com
Monday, 9 December 2024
zacks.com
Thursday, 5 December 2024
businesswire.com
zacks.com
Friday, 29 November 2024
zacks.com
zacks.com
Thursday, 28 November 2024
zacks.com
businesswire.com
Wednesday, 27 November 2024
globenewswire.com
Monday, 25 November 2024
zacks.com
Friday, 22 November 2024
zacks.com
zacks.com
Wednesday, 13 November 2024
zacks.com
Monday, 11 November 2024
zacks.com
Friday, 8 November 2024
zacks.com
Thursday, 7 November 2024
seekingalpha.com
zacks.com
Wednesday, 6 November 2024
zacks.com
zacks.com
reuters.com
Monday, 4 November 2024
zacks.com
zacks.com
globenewswire.com
Tuesday, 29 October 2024
globenewswire.com
Friday, 11 October 2024
zacks.com
Thursday, 10 October 2024
globenewswire.com
globenewswire.com
Monday, 7 October 2024
globenewswire.com
  • What's the price of Qiagen N.V. stock today?

    One share of Qiagen N.V. stock can currently be purchased for approximately $48.1.

  • When is Qiagen N.V.'s next earnings date?

    Unfortunately, Qiagen N.V.'s (QGEN) next earnings date is currently unknown.

  • Does Qiagen N.V. pay dividends?

    Yes, Qiagen N.V. pays dividends and its trailing 12-month yield is 2.93% with 0% payout ratio. The last Qiagen N.V. stock dividend of $1.08 was paid on 31 Jan 2017.

  • How much money does Qiagen N.V. make?

    Qiagen N.V. has a market capitalization of 9.94B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 8.23% to 1.97B US dollars.

  • What is Qiagen N.V.'s stock symbol?

    Qiagen N.V. is traded on the NYSE under the ticker symbol "QGEN".

  • What is Qiagen N.V.'s primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of Qiagen N.V.?

    Shares of Qiagen N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Qiagen N.V.'s key executives?

    Qiagen N.V.'s management team includes the following people:

    • Mr. Thierry Bernard Chief Executive Officer, MD & Member of Management Board(age: 60, pay: $2,410,000)
    • Dr. Roland Sackers Chief Financial Officer, MD & Member of Management Board(age: 57, pay: $977,500)
  • How many employees does Qiagen N.V. have?

    As Jul 2024, Qiagen N.V. employs 5,900 workers, which is 14% more then previous quarter.

  • When Qiagen N.V. went public?

    Qiagen N.V. is publicly traded company for more then 29 years since IPO on 28 Jun 1996.

  • What is Qiagen N.V.'s official website?

    The official website for Qiagen N.V. is qiagen.com.

  • How can i contact Qiagen N.V.?

    Qiagen N.V. can be reached via phone at +31 77 355 6600.

  • What is Qiagen N.V. stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for Qiagen N.V. in the last 12 months, the avarage price target is $49. The average price target represents a 1.87% change from the last price of $48.1.

Qiagen N.V. company profile:

Qiagen N.V.

qiagen.com
Exchange:

NYSE

Full time employees:

5,800

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Hulsterweg 82
Venlo, 5912 PL

CIK: 0001015820
ISIN: NL0015001WM6
CUSIP: N72482123